The short version
Only one company currently supplies this market — there is no backup if it stumbles. Historically, drugs in this position went on to a new shortage within 90 days about 0.6% of the time — roughly 4× the typical drug (0.1%).
Market view
certolizumab pegol · Injection, Powder, Lyophilized, For Solution
1 marketed package NDCs · 1 active manufacturer
Most dispensed: 200 mg/mL · Injection, Solution · #2 syringe, glass/carton / 1 ml in 1 syringe, glass · 200 mg/mL · Injection, Solution · #3 cartons/box / 2 syringe, glass in 1 carton / 1 ml in 1 syringe, glass
What changed in the last 90 days
Every detected change for certolizumab pegol, newest first — price moves, shortages, recalls, and manufacturers entering or leaving. Detected by comparing each day’s federal data against the day before.
Same drug class
Other molecules FDA puts in Tumor Necrosis Factor Blocker, with whether each is in shortage right now. Same class is not the same drug — substitution is a clinical decision, and this is a supply picture, not a recommendation.
Common questions
- Is Certolizumab pegol in shortage right now?
- No. FDA does not currently list Certolizumab pegol in shortage. This page is rebuilt every morning from FDA's shortage database, so a new posting appears here the day it is published.
- Who makes Certolizumab pegol?
- 4 companies have marketed Certolizumab pegol in the last 30 days, according to the FDA NDC Directory. Every manufacturer and package is listed on this page.
- What does Certolizumab pegol cost?
- The typical pharmacy pays about $6,094.03 per unit, based on the most recent CMS NADAC survey of actual acquisition costs. That is what the pharmacy pays for the drug itself — not the cash price, and not what an insurer is billed.
All marketed products
Expand a strength to see its dosage forms, then package sizes, then each manufacturer and NDC. Click an NDC for its full detail page.